首页> 外文期刊>Future oncology >Pleurectomy/decortication and hyperthermic intrapleural chemotherapy for malignant pleural mesothelioma: initial experience
【24h】

Pleurectomy/decortication and hyperthermic intrapleural chemotherapy for malignant pleural mesothelioma: initial experience

机译:恶性胸膜间皮瘤的胸膜切除/去皮和热胸腔内化疗:初步经验

获取原文
获取原文并翻译 | 示例
           

摘要

Cytoreductive surgery and hyperthermic intraoperative intrapleural chemotherapy (HITHOC) are a known option for malignant pleural mesothelioma (MPM). This prospective study was started to prove that pleurectomy/decortication and HITHOC could be successfully performed in a low volume center. Criteria of inclusion were a proven diagnosis of MPM, early-stage disease and good performance status. Six consecutive patients were enrolled. After pleurectomy/decortication, intrapleural cisplatin was administered for 60 min at 42.5 degrees C. Wedge resections and diaphragmatic reconstruction were added in two and one patient, respectively. Morbidity was 16.6%. Mortality was nil. Hospital stay was 7.8 days. Mean survival was 21.5 months (range: 6-30). This small experience confirms that pleurectomy/decortication and HITHOC are a good therapeutic option in the multimodality treatment of MPM. A randomized controlled trial is necessary.
机译:恶性胸膜间皮瘤(MPM)的已知方法是进行细胞减少手术和术中高温热胸腔内化疗(HITHOC)。这项前瞻性研究开始证明胸膜切除术/去皮和HITHOC可在低容量中心成功进行。纳入标准是MPM,早期疾病和良好表现状态的可靠诊断。连续六名患者入选。胸膜切除/脱皮后,在42.5摄氏度下进行60min胸腔内顺铂治疗。分别在两名和一名患者中进行楔形切除和diaphragm肌再造。发病率为16.6%。死亡率为零。住院7.8天。平均生存期为21.5个月(范围:6-30)。很少的经验证明,在MPM的多模式治疗中,胸膜切除/去皮和HITHOC是很好的治疗选择。一项随机对照试验是必要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号